Use of step therapy protocols for the treatment of neurological conditions prohibited.
Summary
HF4357 would prohibit health plans from using step therapy protocols for drugs used to treat neurological conditions when the drug is FDA-approved, included on the plan’s formulary, and used consistently with an FDA-approved indication and a clinical practice guideline. In practical terms, the bill would prevent insurers from requiring patients with neurological disorders to try less-preferred medications first before accessing a covered medication that meets those criteria.
The bill defines “neurological condition” broadly as a disorder resulting from accident or illness that impairs neurological function, and it relies on existing Minnesota law for the definition of “step therapy protocol” and “clinical practice guideline.” The prohibition would apply to health plans offered, issued, or renewed on or after January 1, 2027.
Impact
HF4357 would add a new section to Minnesota Statutes chapter 62Q governing health plan coverage. It would limit insurer utilization-management practices for neurological treatments by carving out an exception to step therapy requirements for qualifying FDA-approved drugs. The bill would affect health insurers, health plans, enrollees with neurological conditions, and prescribing clinicians, and it would likely increase access to certain medications while reducing insurer flexibility to require stepwise treatment sequencing in this area.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears supportive of patient access and treatment continuity, with the bill framed as a consumer-protection measure for people with neurological conditions. There is no documented opposition in the supplied record, but the policy direction suggests a balance between patient access and insurer cost-management interests.
Contention
The main policy tension is between patient access to clinically appropriate neurological medications and health plan efforts to manage costs and encourage use of lower-cost or preferred therapies through step therapy. Supporters would likely emphasize avoiding delays in treatment for patients with serious neurological disorders, while potential critics may argue the bill restricts utilization review tools and could increase premiums or reduce formulary management flexibility. No specific stakeholder objections or amendments are included in the provided record.